MX2012009074A - Compuestos de urea pirrolo [2, 3-d] pirimidina como inhibidores de janus quinasa. - Google Patents

Compuestos de urea pirrolo [2, 3-d] pirimidina como inhibidores de janus quinasa.

Info

Publication number
MX2012009074A
MX2012009074A MX2012009074A MX2012009074A MX2012009074A MX 2012009074 A MX2012009074 A MX 2012009074A MX 2012009074 A MX2012009074 A MX 2012009074A MX 2012009074 A MX2012009074 A MX 2012009074A MX 2012009074 A MX2012009074 A MX 2012009074A
Authority
MX
Mexico
Prior art keywords
pyrrolo
urea compounds
jak inhibitors
compounds
pyrimidine
Prior art date
Application number
MX2012009074A
Other languages
English (en)
Spanish (es)
Inventor
Timothy Allen Johnson
Ashley FENWICK
Graham M Kyne
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2012009074A publication Critical patent/MX2012009074A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2012009074A 2010-02-05 2011-01-24 Compuestos de urea pirrolo [2, 3-d] pirimidina como inhibidores de janus quinasa. MX2012009074A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30191510P 2010-02-05 2010-02-05
PCT/US2011/022216 WO2011097087A1 (en) 2010-02-05 2011-01-24 Pyrrolo [ 2, 3 - d] pyrimidine urea compounds as jak inhibitors

Publications (1)

Publication Number Publication Date
MX2012009074A true MX2012009074A (es) 2012-08-23

Family

ID=43629121

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012009074A MX2012009074A (es) 2010-02-05 2011-01-24 Compuestos de urea pirrolo [2, 3-d] pirimidina como inhibidores de janus quinasa.

Country Status (9)

Country Link
US (1) US20120309776A1 (enExample)
EP (1) EP2531508A1 (enExample)
JP (1) JP2013518882A (enExample)
CN (1) CN102822177A (enExample)
AU (1) AU2011213198B2 (enExample)
BR (1) BR112012019511A2 (enExample)
CA (1) CA2788071A1 (enExample)
MX (1) MX2012009074A (enExample)
WO (1) WO2011097087A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2474545T (pt) 2005-12-13 2017-02-14 Incyte Holdings Corp Pirrolo[2,3-b]piridinas e pirrolo[2,3-b]pirimidinas substituídas com heteroarilo como inibidores de janus quinase
JP2015528501A (ja) * 2012-09-12 2015-09-28 ライジェル ファーマシューティカルズ， インコーポレイテッド 白斑の治療法
TWI761825B (zh) 2012-11-15 2022-04-21 美商英塞特控股公司 盧梭利替尼之緩釋性劑型
CN103896946B (zh) * 2012-12-28 2018-04-03 浙江导明医药科技有限公司 用于预防及治疗多种自身免疫疾病的新化合物
WO2014118388A1 (en) 2013-02-04 2014-08-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for assaying jak2 activity in red blood cells and uses thereof
US20140343034A1 (en) * 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
ES2655074T3 (es) * 2013-06-07 2018-02-16 Jiangsu Hengrui Medicine Co. Ltd. Bisulfato de inhibidor de quinasa Janus (JAK) y procedimiento de preparación del mismo
WO2015021153A1 (en) 2013-08-07 2015-02-12 Incyte Corporation Sustained release dosage forms for a jak1 inhibitor
CN105732637B (zh) * 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
CA3003283A1 (en) * 2015-11-24 2017-06-01 Theravance Biopharma R&D Ip, Llc Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease
JP7096592B2 (ja) 2016-02-16 2022-07-06 ワシントン・ユニバーシティ Ｊａｋ阻害剤およびこれらの利用
WO2018165250A1 (en) 2017-03-08 2018-09-13 Theravance Biopharma R&D Ip, Llc Glucuronide prodrugs of tofacitinib
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
EP3610264A1 (en) 2017-04-13 2020-02-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
US10745405B2 (en) 2017-05-23 2020-08-18 Theravance Biopharma R&D Ip, Llc Glucuronide prodrugs of Janus kinase inhibitors
EP3609903A1 (en) 2017-05-23 2020-02-19 Theravance Biopharma R&D IP, LLC Thiocarbamate prodrugs of tofacitinib
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0831829B1 (en) * 1995-06-07 2003-08-20 Pfizer Inc. Heterocyclic ring-fused pyrimidine derivatives
KR100415791B1 (ko) 1998-06-19 2004-01-24 화이자 프로덕츠 인코포레이티드 피롤로[2,3-디]피리미딘 화합물
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
NZ518884A (en) 1999-12-10 2004-02-27 Pfizer Prod Inc Pyrrolo[2,3-d]pyrimidine compounds
DK1686130T3 (da) * 2000-06-26 2009-04-06 Pfizer Prod Inc Pyrrolo-[2,3-d]-pyrimidinforbindelser som immunsuppressive midler
WO2002002506A2 (en) * 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
RS20050380A (sr) 2002-11-21 2007-11-15 Pfizer Products Inc., Derivati 3-aminopiperidina i postupci njihove proizvodnje
US7732237B2 (en) 2005-06-27 2010-06-08 The Regents Of The University Of California Quantum dot based optoelectronic device and method of making same
DK1913000T3 (da) * 2005-07-29 2012-03-12 Pfizer Prod Inc Pyrrolo[2,3-D]pyrimidinderivater; deres mellemprodukter og syntese
WO2008029237A2 (en) * 2006-09-05 2008-03-13 Pfizer Products Inc. Combination therapies for rheumatoid arthritis

Also Published As

Publication number Publication date
WO2011097087A1 (en) 2011-08-11
CN102822177A (zh) 2012-12-12
JP2013518882A (ja) 2013-05-23
AU2011213198A1 (en) 2012-08-09
CA2788071A1 (en) 2011-08-11
BR112012019511A2 (pt) 2016-08-23
US20120309776A1 (en) 2012-12-06
AU2011213198B2 (en) 2014-04-24
EP2531508A1 (en) 2012-12-12

Similar Documents

Publication Publication Date Title
MX2012009074A (es) Compuestos de urea pirrolo [2, 3-d] pirimidina como inhibidores de janus quinasa.
IN2012DN02577A (enExample)
PH12015501779B1 (en) Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus- related kinases (jak)
UY32059A (es) Compuestos de pirrolo [2,3-d] pirimidina
PH12012502334A1 (en) Heteroaryl imidazolone derivatives as jak inhibitors
PH12016500938A1 (en) Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
MY156727A (en) N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
GEP201706620B (en) NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS
HK1202541A1 (en) 2-amino, 6-phenyl substituted pyrido [2, 3 - d] pyrimidine derivatives useful as raf kinase inhibitors
MX2015010858A (es) Formas solidas de un inhbidor de cdk4/6 selectivo.
TW201713640A (en) Bruton's tyrosine kinase inhibitors
WO2012007345A3 (en) Substituted imidazo[1,2-a]pyrimidines and -pyridines
PH12014500103A1 (en) Pyridin-2(1h)-one derivatives as jak inhibitors
PH12012501164A1 (en) Imidazopyridine derivatives as jak inhibitors
WO2012054364A3 (en) Bicyclic diamines as janus kinase inhibitors
WO2013004995A8 (en) Pyrimidinone compounds and their use
JO2822B1 (en) Inhibitors of the enzyme kinase P70 S6 and AKT
SI2658844T1 (sl) Novi derivati pirimidina, njihova priprava in njihova farmacevtska uporaba kot inhibitorje AKT(PKB) fosforilacije
CY1115106T1 (el) Ενωσεις πυρρολο[2,3-d]πυριμιδινης
TN2010000363A1 (en) Pyrrolo [2,3-d] pyridines and use thereof as tyrosine kinase inhibitors

Legal Events

Date Code Title Description
GB Transfer or rights
HC Change of company name or juridical status